Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis

Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis

Abstract Background Atypical hemolytic uremic syndrome (aHUS) triggered by pregnancy is a rare disease caused by dysregulation of the alternative complement pathway that occurs in approximately 1 in 25,000 pregnancies. The 311 phase 3 trial (NCT02949128) showed that ravulizumab, a long-acting C5 inh...

Full description

Bibliographic Details
Main Authors: Anja Gäckler, Ulf Schönermarck, Vladimir Dobronravov, Gaetano La Manna, Andrew Denker, Peng Liu, Maria Vinogradova, Sung-Soo Yoon, Manuel Praga
Format: Article
Language:English
Published: BMC 2021-01-01
Series:BMC Nephrology
Subjects:
Ravulizumab
Thrombotic microangiopathy
Pregnancy microangiopathies
Atypical hemolytic uremic syndrome
Online Access:https://doi.org/10.1186/s12882-020-02190-0

Internet

https://doi.org/10.1186/s12882-020-02190-0

Similar Items